Nov 27, 2019
ASX/NASDAQ ANNOUNCEMENT: Re-domiciliation to the United States
Oct 31, 2019
Appendix 4C: Quarterly Cash Flow Report
Sep 30, 2019
Benitec Biopharma Limited Announces US$2.25 Million Registered Direct Offering
Sep 16, 2019
Benitec Biopharma Provides Update on BB-301 Oculopharyngeal Muscular Dystrophy (OPMD) Program
Jul 31, 2019
ASX/NASDAQ ANNOUNCEMENT Appendix 4C: Quarterly Cash Flow Report
Jun 06, 2019
Update on Oculopharyngeal Muscular Dystrophy Program
Sep 19, 2018
Benitec Biopharma Announces the Appointment of Gregory R. Reyes, M.D., Ph.D. as Senior Scientific Advisor
Jul 08, 2018
Benitec Announces Global Licensing Agreement for BB-301 for Treatment of Oculopharyngeal Muscular Dystrophy and Broad Platform Collaboration with Axovant
May 31, 2018
Benitec Biopharma reports financial results for the 2018 fiscal third quarter and provides operational update
May 15, 2018
Benitec to present OPMD data at the American Society of Gene and Cell Therapy Meeting
May 03, 2018
Benitec to Host Investor Webinar on the Company's Oculopharyngeal Muscular Dystrophy (OPMD) Program
Apr 24, 2018
ASX/NASDAQ Announcement
Mar 05, 2018
Benitec Biopharma Launches its Phase 2 Oncology Study in Australia
Feb 22, 2018
Benitec Biopharma reports financial results for the 2018 fiscal second quarter and provides operational update
Jan 23, 2018
Federal R&D Tax Credit Received
Jan 16, 2018
Benitec receives U.S. Orphan Drug Designation for BB-301, its ddRNAi therapeutic for the treatment of oculopharyngeal muscular dystrophy
Nov 27, 2017
Benitec Biopharma provides update on OPMD orphan disease program
Oct 18, 2017
U.S. patent granted for Benitec hepatitis B program
Aug 08, 2017
Benitec Biopharma advances OPMD orphan disease program